Health and Me

Ishita Roy

French Scientist Who Invented Abortion Pills Dies At 98

For the longest women's health have been ignored in medicines. While there is progress, but it still needs to go in a long way. However, whatever has been succeeded has not always been easy. But, imagine a life without options, with a Plan B? Thanks to <span>Étienne-Émile Baulieu</span>, the French scientist <span>who</span> passed away at the age of 98 in his home in Paris for developing the <span>abortion pill</span>. 

Renowned for his groundbreaking work on steroid hormones, Baulieu dedicated his career to advancing scientific knowledge and championing individual freedom. His institute remembered him as someone whose work was shaped by a deep commitment to progress, human dignity, and better living.

Also Read:<a href="https://www.healthandme.com/health-wellness/inside-minneapolis-silent-room-a-place-that-makes-you-question-if-silence-heals-or-haunts-article-151773292" data-type="tilCustomLink" target="_blank"> Inside Minneapolis' Silent Room: A Place That Makes You Question If Silence Heals or Haunts</a>

<h4>All About the <span rel="noindex">Abortion</span> Pill Inventor?</h4>

Born Étienne Blum in Strasbourg on December 12, 1926, Baulieu changed his name when he joined the French Resistance at the age of 15 during the Nazi occupation. This early experience shaped his lifelong values of liberty and courage. After completing medical and science doctorates, he began pioneering research in endocrinology and hormonal medicine.

<h2>Abortion Pill: An Invention That Changed the Lives Of Millions</h2>

In 1982, Baulieu developed RU-486—commonly known as <span>mifepristone</span> or the abortion pill. The drug offered a non-invasive, medically safe alternative to surgical abortion. It was a turning point in reproductive healthcare, providing millions of women worldwide with a private and less traumatic method of ending a pregnancy.

Despite its significance, the pill attracted controversy. Baulieu faced severe backlash, including threats from anti-abortion groups. Even today, access to the medication is restricted or banned in certain countries. Yet, it remains one of the most widely used abortion methods, especially in places where surgical access is limited.

Also Read: <a href="https://www.healthandme.com/health-wellness/national-cancer-survivors-day-more-than-a-diagnosis-cancer-survivors-share-the-small-wins-that-helped-them-heal-article-151770333" data-type="tilCustomLink" target="_blank">Cancer Survivors Share The Small Wins That Helped Them Heal</a>

<h2>Abortion Pill: The Impact, The Challenges</h2>

Since its development, mifepristone has been approved in over 100 countries. The World Health Organization included it on its list of essential medicines in 2010. Still, its availability remains a battleground, particularly in the United States, where recent legal rulings have challenged access to abortion pills.

Baulieu continued to defend his work until the end, noting in a 2023 interview that restricting access to the drug undermines decades of progress toward gender equality and freedom.

His research extended into the fields of aging and mental health. His work on the hormone DHEA led to significant findings about neurosteroids, and he pursued treatments for Alzheimer’s and depression. In 2008, he founded the Institut Baulieu to focus on preventing and understanding neurodegenerative diseases.

He received France’s highest honors, including the Grand Cross of the Legion of Honour and leadership roles in the Academy of Sciences. Leaders including French President Emmanuel Macron praised him as a visionary who changed the world. Macron wrote, “Few French people have changed the world to such an extent,” calling Baulieu a “beacon of courage.”

Also Read: <a href="https://www.healthandme.com/health-news/type-2-diabetes-and-high-blood-pressure-now-affect-1-in-8-americans-study-links-combo-to-early-death-risk-article-151766208" data-type="tilCustomLink" target="_blank">Type 2 Diabetes And High Blood Pressure Now Affect 1 In 8 Americans, Study Links Combo To Early Death Risk</a>

Baulieu is survived by his wife, three children, eight grandchildren, and nine great-grandchildren. His work—especially the invention of the abortion pill—remains a powerful symbol of science serving humanity.

Health Conditions A-Z

health

abortion pill inventor death news

abortion inventor dies at 98

health news

french scientist who invented abortion pills dies

abortion

abortion pill

mifepristone

Étienne-Émile Baulieu

Not Cleaning Your Face Before Sleeping? These Tiny Bugs Might Be Feasting On Your Skin

What Is Sleep Banking?  How ‘Preloading’ Rest Before A Busy Week Beat Burnout

Twisting Yoga Poses For Your Upper Back Strength

Health News

Heatwave To Monsoon: Health Concerns With Seasonal Changes

Standing Exercises That Help You Burn Calories

Reasons To Do Dancing As A Workout

Why Summer Fruits Are A Great Addition To Your Diet?

What Should You Avoid For Your Bladder?

Lower-Body Exercises For Strong Foundation

Healthy Drinks That Improve Your Digestion

World Tobacco Day: Unexpected Ways Smoking Can Affect You

Seasonal Mood Swings? How Weather Affects Mental Health

Is Calorie Counting Healthy? Dos And Don’ts

Heat-Related Illnesses That You Should Know

Menstrual Hygiene Day: Tips On Period Hygiene

​Add These High Protein Vegetarian Meals To Your Diet​

Top 10 Workouts That Burn Most Calorie

Makhana Season – Healthy &amp; Quick Foxnut Recipes

Monsoon Ahead – Tips On Building Rainy Season Immunity

Do You Have Prickly Heat Rash – Symptoms, Causes And Treatment

Healthy No-Cook Recipes You Can Try

How Do You Calorie Count – Numbers And Nutrients

Unexpected Signs Of Dehydration – Safety And Precaution Measures

Leg Exercises You Can Do At Home To Build Strength

Foods That Promote Skin Elasticity

Must-Do Chest Exercises You Can Try At Home

What Are The Symptoms Of JN.1 COVID-19 Strain?

Why Does Sleeping Become Harder As You Age?

High-Fiber Healthy Drinks You Should Try

10 Dumbbell Exercise Variations For Upper-Body Strength

A Parent’s Guide To Pets: Important Points To Consider For Your Child’s Health

Food Anxiety Is Real – How Your Food Intake Affects Your Anxiety

World Osteoporosis Month: Ways To Strengthen Your Bones

Brain Exercises To Keep You Cognitively Sharp

Easy Recipes To Make When You Don’t Wish To Cook

Physical Signs Of High Cortisol

9 Healthy Plant-Based Protein Rich Dishes To Try

What Happens When You Have Low Blood Pressure?

Throw These Toxic Bathroom Items Away To Protect Your Health

This Is What Cricket Superstar Virat Kohli Eats In A Day

Signs You Are Experiencing Sensory Overload

Shoulder Exercises You Should Do For Defined Shoulders

Best Foods To Eat When You Are Fasting

For the longest women's health have been ignored in medicines. While there is progress, but it still needs to go in a long way. However, whatever has been succeeded has not always been easy. But, imagine a life without options, with a Plan B? Thanks to Étienne-Émile Baulieu, the French scientist who passed away at the age of 98 in his home in Paris for developing the abortion pill. Renowned for his groundbreaking work on steroid hormones, Baulieu dedicated his career to advancing scientific knowledge and championing individual freedom. His institute remembered him as someone whose work was shaped by a deep commitment to progress, human dignity, and better living.Also Read: Inside Minneapolis' Silent Room: A Place That Makes You Question If Silence Heals or HauntsAll About the Abortion Pill Inventor?Born Étienne Blum in Strasbourg on December 12, 1926, Baulieu changed his name when he joined the French Resistance at the age of 15 during the Nazi occupation. This early experience shaped his lifelong values of liberty and courage. After completing medical and science doctorates, he began pioneering research in endocrinology and hormonal medicine.Abortion Pill: An Invention That Changed the Lives Of MillionsIn 1982, Baulieu developed RU-486—commonly known as mifepristone or the abortion pill. The drug offered a non-invasive, medically safe alternative to surgical abortion. It was a turning point in reproductive healthcare, providing millions of women worldwide with a private and less traumatic method of ending a pregnancy.Despite its significance, the pill attracted controversy. Baulieu faced severe backlash, including threats from anti-abortion groups. Even today, access to the medication is restricted or banned in certain countries. Yet, it remains one of the most widely used abortion methods, especially in places where surgical access is limited.Also Read: Cancer Survivors Share The Small Wins That Helped Them HealAbortion Pill: The Impact, The ChallengesSince its development, mifepristone has been approved in over 100 countries. The World Health Organization included it on its list of essential medicines in 2010. Still, its availability remains a battleground, particularly in the United States, where recent legal rulings have challenged access to abortion pills.Baulieu continued to defend his work until the end, noting in a 2023 interview that restricting access to the drug undermines decades of progress toward gender equality and freedom.His research extended into the fields of aging and mental health. His work on the hormone DHEA led to significant findings about neurosteroids, and he pursued treatments for Alzheimer’s and depression. In 2008, he founded the Institut Baulieu to focus on preventing and understanding neurodegenerative diseases.He received France’s highest honors, including the Grand Cross of the Legion of Honour and leadership roles in the Academy of Sciences. Leaders including French President Emmanuel Macron praised him as a visionary who changed the world. Macron wrote, “Few French people have changed the world to such an extent,” calling Baulieu a “beacon of courage.”Also Read: Type 2 Diabetes And High Blood Pressure Now Affect 1 In 8 Americans, Study Links Combo To Early Death RiskBaulieu is survived by his wife, three children, eight grandchildren, and nine great-grandchildren. His work—especially the invention of the abortion pill—remains a powerful symbol of science serving humanity.

french scientist who invented abortion pills dies at 98

Tanya Dutt

WHO Issues Recommendations To Fight RSV In Babies- How Parents Can Protect Their Newborns

CDC Recommends All International Travelers To Get Measles Vaccine

cdc recommends all international travelers to get measles vaccine

Know All About The Candidozyma Auris, The Fungal Pathogen And A Rising Health Threat

know all about the candidozyma auris, the fungal pathogen and a rising health threat

India Records 3,395 Active COVID-19 Cases, 26 Deaths, Kerala And Maharashtra Among Worst-Hit States

india records 3,395 active covid-19 cases, 26 deaths, kerala and maharashtra among worst-hit states

Fluoride Removal From Drinking Water Could Trigger Millions More Cavities In US Kids , Study Warns

fluoride removal from drinking water could trigger millions more cavities in us kids , study warns

The World Health Organization (WHO) has issued its first-ever immunization recommendations against Respiratory Syncytial Virus (RSV) — a common but potentially deadly respiratory infection that disproportionately affects newborns and young children. With RSV accounting for nearly 100,000 deaths and over 3.6 million hospitalizations annually among children under five, these new guidelines come as a much-needed global health intervention, especially in low- and middle-income countries where access to oxygen and hydration remains limited.

As international attention shifts toward this preventable yet dangerous illness, WHO’s new recommendations bring renewed hope for parents and caregivers — offering medically backed, preventive tools that could significantly reduce RSV-related hospitalizations and infant mortality worldwide.

Though RSV may mimic the common cold in many cases, its effects in infants can be devastating. The virus is highly contagious and particularly dangerous for babies under six months, especially those born prematurely or with weakened immune systems. What begins as a mild cough or runny nose can escalate to pneumonia or bronchiolitis, requiring urgent hospitalization.

Dr. Kate O’Brien, Director of Immunization, Vaccines, and Biologicals at WHO, explains, “RSV is an incredibly infectious virus that infects people of all ages, but is especially harmful to infants, particularly those born premature, when they are most vulnerable to severe disease.”

Despite its massive global impact, RSV has been largely underprioritized in global health discussions — until now.

<h2>WHO’s First Global Immunization Guidance on RSV</h2>

In a new and landmark position paper released on May 30, 2025, WHO introduced its first comprehensive immunization guidance to protect infants from RSV. The document outlines two key immunization products:

<ul><li>RSVpreF Maternal Vaccine</li><li>Nirsevimab Monoclonal Antibody Injection</li></ul>

These immunizations were recommended for global use by the Strategic Advisory Group of Experts on Immunization (SAGE) in September 2024. The maternal vaccine also received WHO prequalification in March 2025 — a move that allows UN agencies and global health funders to begin procurement and deployment across nations.

This scientific breakthrough represents more than just a pharmaceutical advance. It marks a strategic turning point in pediatric health — a chance to proactively prevent rather than react to one of the leading causes of infant respiratory distress and death.

The RSVpreF maternal vaccine is designed for administration during the third trimester of pregnancy, ideally from the 28th week onwards. Administered during routine antenatal check-ups, the vaccine prompts the mother’s immune system to produce RSV-specific antibodies, which are then transferred to the fetus through the placenta.

This passive immunity equips the newborn with a layer of defense right from birth, a critical window of vulnerability when babies are most at risk of severe RSV outcomes.

Maternal immunization is especially beneficial in countries where healthcare access is limited post-delivery, offering early protection before the baby can be brought to pediatric check-ups or immunization visits.

<h2>How Does Monoclonal Antibody Protection Works?</h2>

Nirsevimab, the second recommended intervention, is a monoclonal antibody administered as a single injection shortly after birth or before hospital discharge. For infants not vaccinated at birth, the antibody can be administered during the first health check-up or just before RSV season begins — especially relevant in regions where RSV follows seasonal patterns.

Unlike traditional vaccines that train the body to build its own immune response, monoclonal antibodies provide immediate protection. A single dose can protect infants for at least five months — long enough to cover an entire RSV season.

WHO emphasizes that the greatest benefit will be seen in babies under six months of age, though infants up to 12 months may also derive protective benefits.

According to WHO, 97% of RSV-related infant deaths occur in low- and middle-income countries — largely due to a lack of timely medical care like oxygen therapy or intravenous hydration. The rollout of these preventive tools offers these regions an unprecedented opportunity to fight RSV on the frontlines.

These immunization products can also significantly reduce hospital burden in high-income countries, freeing up pediatric intensive care units (ICUs) and reducing parental anxiety during RSV season.

The WHO’s position paper is not only a scientific guide — it's a strategic blueprint for governments, health ministries, and funding agencies to incorporate RSV prevention into national immunization programs.

<h2>What Parents Can Do to Protect Their Newborns From RSV?</h2>

While global immunization strategies are being rolled out, individual parents still play a crucial role in protecting their newborns from RSV. Here's how:

<h4>1. Ask About Maternal Vaccination During Pregnancy</h4>

If you’re pregnant, speak with your healthcare provider about receiving the RSVpreF vaccine during your third trimester. It can be safely administered as part of your regular antenatal care, and offers vital early protection to your newborn.

<h4>2. Ensure Timely Infant Immunization</h4>

If the monoclonal antibody nirsevimab is available in your country, ensure your baby receives the injection either at birth or during their first pediatric visit. In areas with seasonal RSV peaks, schedule the dose ahead of the expected surge.

<h4>3. Limit Infant Exposure During RSV Season</h4>

Avoid crowded public places during RSV season, especially with newborns. RSV spreads through respiratory droplets and contaminated surfaces, making indoor public gatherings a high-risk environment.

<h4>4. Practice Hand Hygiene and Clean Surfaces</h4>

Ensure everyone who comes into contact with your baby washes their hands thoroughly. Disinfect frequently touched surfaces — RSV can survive on hard surfaces for hours.

If your baby shows signs of difficulty breathing, rapid breathing, persistent cough, or a bluish tint around the lips or fingernails, seek immediate medical attention. RSV can escalate quickly in infants.

With WHO’s endorsement of two powerful preventive options, RSV no longer needs to be a silent killer. The combination of maternal vaccination and infant monoclonal antibodies brings renewed hope to millions of parents — especially those in under-resourced areas — who’ve long been without any effective preventive tools.

As Dr. O’Brien puts it, “The WHO-recommended RSV immunization products can transform the fight against severe RSV disease, dramatically reduce hospitalizations, and deaths, ultimately saving many infant lives globally.”

rsv in infants

who rsv guidelines

rsv vaccine for newborns

nirsevimab for babies

maternal rsv vaccine

protect newborns from rsv

rsv prevention 2025

The World Health Organization (WHO) has issued its first-ever immunization recommendations against Respiratory Syncytial Virus (RSV) — a common but potentially deadly respiratory infection that disproportionately affects newborns and young children. With RSV accounting for nearly 100,000 deaths and over 3.6 million hospitalizations annually among children under five, these new guidelines come as a much-needed global health intervention, especially in low- and middle-income countries where access to oxygen and hydration remains limited.As international attention shifts toward this preventable yet dangerous illness, WHO’s new recommendations bring renewed hope for parents and caregivers — offering medically backed, preventive tools that could significantly reduce RSV-related hospitalizations and infant mortality worldwide.Though RSV may mimic the common cold in many cases, its effects in infants can be devastating. The virus is highly contagious and particularly dangerous for babies under six months, especially those born prematurely or with weakened immune systems. What begins as a mild cough or runny nose can escalate to pneumonia or bronchiolitis, requiring urgent hospitalization.Dr. Kate O’Brien, Director of Immunization, Vaccines, and Biologicals at WHO, explains, “RSV is an incredibly infectious virus that infects people of all ages, but is especially harmful to infants, particularly those born premature, when they are most vulnerable to severe disease.”Despite its massive global impact, RSV has been largely underprioritized in global health discussions — until now.WHO’s First Global Immunization Guidance on RSVIn a new and landmark position paper released on May 30, 2025, WHO introduced its first comprehensive immunization guidance to protect infants from RSV. The document outlines two key immunization products:RSVpreF Maternal VaccineNirsevimab Monoclonal Antibody InjectionThese immunizations were recommended for global use by the Strategic Advisory Group of Experts on Immunization (SAGE) in September 2024. The maternal vaccine also received WHO prequalification in March 2025 — a move that allows UN agencies and global health funders to begin procurement and deployment across nations.This scientific breakthrough represents more than just a pharmaceutical advance. It marks a strategic turning point in pediatric health — a chance to proactively prevent rather than react to one of the leading causes of infant respiratory distress and death.What is Maternal Immunization?The RSVpreF maternal vaccine is designed for administration during the third trimester of pregnancy, ideally from the 28th week onwards. Administered during routine antenatal check-ups, the vaccine prompts the mother’s immune system to produce RSV-specific antibodies, which are then transferred to the fetus through the placenta.This passive immunity equips the newborn with a layer of defense right from birth, a critical window of vulnerability when babies are most at risk of severe RSV outcomes.Maternal immunization is especially beneficial in countries where healthcare access is limited post-delivery, offering early protection before the baby can be brought to pediatric check-ups or immunization visits.How Does Monoclonal Antibody Protection Works?Nirsevimab, the second recommended intervention, is a monoclonal antibody administered as a single injection shortly after birth or before hospital discharge. For infants not vaccinated at birth, the antibody can be administered during the first health check-up or just before RSV season begins — especially relevant in regions where RSV follows seasonal patterns.Unlike traditional vaccines that train the body to build its own immune response, monoclonal antibodies provide immediate protection. A single dose can protect infants for at least five months — long enough to cover an entire RSV season.WHO emphasizes that the greatest benefit will be seen in babies under six months of age, though infants up to 12 months may also derive protective benefits.According to WHO, 97% of RSV-related infant deaths occur in low- and middle-income countries — largely due to a lack of timely medical care like oxygen therapy or intravenous hydration. The rollout of these preventive tools offers these regions an unprecedented opportunity to fight RSV on the frontlines.These immunization products can also significantly reduce hospital burden in high-income countries, freeing up pediatric intensive care units (ICUs) and reducing parental anxiety during RSV season.The WHO’s position paper is not only a scientific guide — it's a strategic blueprint for governments, health ministries, and funding agencies to incorporate RSV prevention into national immunization programs.What Parents Can Do to Protect Their Newborns From RSV?While global immunization strategies are being rolled out, individual parents still play a crucial role in protecting their newborns from RSV. Here's how:1. Ask About Maternal Vaccination During PregnancyIf you’re pregnant, speak with your healthcare provider about receiving the RSVpreF vaccine during your third trimester. It can be safely administered as part of your regular antenatal care, and offers vital early protection to your newborn.2. Ensure Timely Infant ImmunizationIf the monoclonal antibody nirsevimab is available in your country, ensure your baby receives the injection either at birth or during their first pediatric visit. In areas with seasonal RSV peaks, schedule the dose ahead of the expected surge.3. Limit Infant Exposure During RSV SeasonAvoid crowded public places during RSV season, especially with newborns. RSV spreads through respiratory droplets and contaminated surfaces, making indoor public gatherings a high-risk environment.4. Practice Hand Hygiene and Clean SurfacesEnsure everyone who comes into contact with your baby washes their hands thoroughly. Disinfect frequently touched surfaces — RSV can survive on hard surfaces for hours.5. Watch for Warning SignsIf your baby shows signs of difficulty breathing, rapid breathing, persistent cough, or a bluish tint around the lips or fingernails, seek immediate medical attention. RSV can escalate quickly in infants.With WHO’s endorsement of two powerful preventive options, RSV no longer needs to be a silent killer. The combination of maternal vaccination and infant monoclonal antibodies brings renewed hope to millions of parents — especially those in under-resourced areas — who’ve long been without any effective preventive tools.As Dr. O’Brien puts it, “The WHO-recommended RSV immunization products can transform the fight against severe RSV disease, dramatically reduce hospitalizations, and deaths, ultimately saving many infant lives globally.”

who issues recommendations to fight rsv in babies- how parents can protect their newborns

Candidozyma Auris, The Fungal Pathogen And A Rising Health Threat

Nutrition

FDA Issues Severe Tomato Recall Warning in Southern US

fda issues severe tomato recall warning in southern us

Type 2 Diabetes And High Blood Pressure Now Affect 1 In 8 Americans, Study Links Combo To Early Death Risk

type 2 diabetes and high blood pressure now affect 1 in 8 americans, study links combo to early death risk

As the world is struggling with the rising COVID-19 cases, another global health threat may be lingering, notes UK Health Security Agency (UKHSA), it is the <span>Candidozyma auris</span>. 

It is a recently discovered fundus, notes the UKHSA, and is a type of microorganism, which can make you ill. We are often surrounded by fungi, but do not realise it. However, there may be some kind which could pose significant health threats and can also spread silently, even in hospitals. This is Candidozyma auris, or the C. auris, which was formerly known as Candida auris. 

C. auris rarely causes infections in healthy people but can be dangerous for those in hospitals—especially patients who are critically ill, have been admitted for long periods, or have weakened immune systems. First discovered in 2009 in a patient’s ear in Japan, it has since spread to over 40 countries across six continents. What makes C. auris particularly worrisome is its ability to survive on surfaces for extended periods, including in hospital settings, and its resistance to many commonly used treatments and disinfectants.

C. auris mainly spreads through contact with contaminated surfaces, medical equipment, or directly from people who carry the <span>fungus</span>. Some individuals may have C. auris on their skin without showing symptoms—this is called colonisation. However, if the fungus enters the body through a wound or medical device like a catheter or drip, it can lead to infection.

In healthcare settings, C. auris can easily pass from one person to another. Colonisation can happen simply by touching surfaces or items that carry the fungus. It has been found on various hospital objects, including bedside equipment, radiators, sinks, windowsills, and medical tools such as thermometers, blood pressure cuffs, and stethoscopes.

<h4>What Are The Illnesses Caused By C. auris?</h4>

C. auris infections can vary in severity. Some people may carry the fungus without any symptoms, while others can develop serious infections in the blood, brain, spinal cord, bones, abdomen, wounds, ears, lungs, or urinary tract. Even those without symptoms can still develop an infection later or spread the fungus to others.

C. auris mainly affects people in hospitals or other healthcare settings, particularly those with weakened immune systems. This includes:

<ul><li>Patients who have received medical care abroad in the past year, especially from countries with ongoing C. auris outbreaks</li><li>Individuals with long hospital stays</li><li>Patients using medical devices that go inside the body (like catheters or IV lines)</li><li>People in intensive care units</li><li>Those who have taken certain antibiotics previously</li><li>People who are colonised (carrying the fungus without symptoms) can do so for months or even years, putting them at ongoing risk of infection and making it easier for the fungus to spread to others.</li></ul>

Candidozyma Auris

uk health news

fungal infection

fungus

As the world is struggling with the rising COVID-19 cases, another global health threat may be lingering, notes UK Health Security Agency (UKHSA), it is the Candidozyma auris. It is a recently discovered fundus, notes the UKHSA, and is a type of microorganism, which can make you ill. We are often surrounded by fungi, but do not realise it. However, there may be some kind which could pose significant health threats and can also spread silently, even in hospitals. This is Candidozyma auris, or the C. auris, which was formerly known as Candida auris. C. auris rarely causes infections in healthy people but can be dangerous for those in hospitals—especially patients who are critically ill, have been admitted for long periods, or have weakened immune systems. First discovered in 2009 in a patient’s ear in Japan, it has since spread to over 40 countries across six continents. What makes C. auris particularly worrisome is its ability to survive on surfaces for extended periods, including in hospital settings, and its resistance to many commonly used treatments and disinfectants.How Does It Spread?C. auris mainly spreads through contact with contaminated surfaces, medical equipment, or directly from people who carry the fungus. Some individuals may have C. auris on their skin without showing symptoms—this is called colonisation. However, if the fungus enters the body through a wound or medical device like a catheter or drip, it can lead to infection.In healthcare settings, C. auris can easily pass from one person to another. Colonisation can happen simply by touching surfaces or items that carry the fungus. It has been found on various hospital objects, including bedside equipment, radiators, sinks, windowsills, and medical tools such as thermometers, blood pressure cuffs, and stethoscopes.What Are The Illnesses Caused By C. auris?C. auris infections can vary in severity. Some people may carry the fungus without any symptoms, while others can develop serious infections in the blood, brain, spinal cord, bones, abdomen, wounds, ears, lungs, or urinary tract. Even those without symptoms can still develop an infection later or spread the fungus to others.Who is at risk?C. auris mainly affects people in hospitals or other healthcare settings, particularly those with weakened immune systems. This includes:Patients who have received medical care abroad in the past year, especially from countries with ongoing C. auris outbreaksIndividuals with long hospital staysPatients using medical devices that go inside the body (like catheters or IV lines)People in intensive care unitsThose who have taken certain antibiotics previouslyPeople who are colonised (carrying the fungus without symptoms) can do so for months or even years, putting them at ongoing risk of infection and making it easier for the fungus to spread to others.

FDA Greenlights Tryptyr for Treating Dry Eye Disease

FDA approves Tryptyr for Dry Eyes Disease

Health & Wellness

New Cancer Therapy Increases Survival Rate By 40%: Study

new cancer therapy increases survival rate by 40%: study

How The Drug 'Creon' Works And Why Its Shortage Is Forcing Cancer Patients To Skip Meals

how the drug 'creon' works and why its shortage is forcing cancer patients to skip meals

Colon Cancer Is Rising In Millennials- But This One Symptom Still Feels Too Embarrassing To Talk About

colon cancer is rising in millennials- but this one symptom still feels too embarrassing to talk about

Fitness

Exercise Proven ‘Better Than Drugs’ To Prevent Colon Cancer Recurrence, Study Trial Shows

exercise proven ‘better than drugs’ to prevent colon cancer recurrence, study trial shows

The U.S. Food and Drug Administration (FDA) has approved Tryptyr (acoltremon ophthalmic solution), the first-in-class TRPM8 receptor agonist, for the treatment of both the signs and symptoms of <span>dry eye disease</span> (DED). This approval marks a significant milestone for patients struggling with limited treatment options and persistent discomfort.

<h4>A New Approach to Managing Dry Eye</h4>

Dry eye disease has long been challenging to treat due to slow onset of relief, poor patient adherence, and general dissatisfaction with existing therapies. Tryptyr offers a novel mechanism of action by stimulating corneal sensory nerves, which helps rapidly boost the eye's natural tear production. The solution will be distributed in single-dose vials, with the recommended dosage being one drop in each eye, twice daily.

<h4>Promising Results from Clinical Trials</h4>

The FDA’s approval was based on data from two phase 3 clinical trials—COMET-2 and COMET-3—involving over 930 patients with a history of dry eye disease. Participants were randomly assigned to receive either Tryptyr or a vehicle solution.

The trials demonstrated significant improvements in natural tear production as early as Day 1. By Day 14, 42.6% of participants in COMET-2 and 53.2% in COMET-3 experienced a ≥10-mm increase in tear production, compared to only 8.2% and 14.4%, respectively, in the control groups. The treatment's effectiveness was consistent through Day 90. The most common side effect reported was mild to moderate pain at the instillation site.

<h4>Expert Reactions and Future Availability</h4>

Dr. Marjan Farid, professor of ophthalmology at the University of California, Irvine, called the approval a meaningful advancement in dry eye management, as is also reported by the US News. “Tryptyr is the first eye drop that stimulates corneal nerves to directly address tear deficiency—a known cause of dry eye disease,” she said in a statement.

The treatment is expected to be launched in the U.S. by Alcon in the third quarter of 2025.

Dry eye disease, also known by terms like dry eye syndrome (DES), ocular surface disease (OSD), and keratoconjunctivitis sicca (KCS), is one of the most common reasons people visit eye doctors. The Tear Film and Ocular Surface Society (TFOS) defines DED as a multifactorial disease of the ocular surface characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory issues.

The tear film itself is about 2 to 5.5 µm thick and is made up of three main components:

<strong>Lipid layer: </strong>Produced by the meibomian glands to reduce tear evaporation.

<strong>Aqueous layer: </strong>The thickest layer, produced by lacrimal glands and responsible for providing hydration and nutrients.

<strong>Mucin layer: </strong>Created by conjunctival goblet cells to help tears spread evenly over the eye’s surface.

While "DES" is commonly used by both patients and clinicians, "DED" better reflects the complex nature of the condition. It accounts for various causes—ranging from evaporative issues to tear deficiency—offering a more comprehensive framework for diagnosis and treatment.

With the approval of Tryptyr, the future of dry eye treatment appears more hopeful than ever.

US health news

dry eye disease

dry eyes cure

health news us

The U.S. Food and Drug Administration (FDA) has approved Tryptyr (acoltremon ophthalmic solution), the first-in-class TRPM8 receptor agonist, for the treatment of both the signs and symptoms of dry eye disease (DED). This approval marks a significant milestone for patients struggling with limited treatment options and persistent discomfort.A New Approach to Managing Dry EyeDry eye disease has long been challenging to treat due to slow onset of relief, poor patient adherence, and general dissatisfaction with existing therapies. Tryptyr offers a novel mechanism of action by stimulating corneal sensory nerves, which helps rapidly boost the eye's natural tear production. The solution will be distributed in single-dose vials, with the recommended dosage being one drop in each eye, twice daily.Promising Results from Clinical TrialsThe FDA’s approval was based on data from two phase 3 clinical trials—COMET-2 and COMET-3—involving over 930 patients with a history of dry eye disease. Participants were randomly assigned to receive either Tryptyr or a vehicle solution.The trials demonstrated significant improvements in natural tear production as early as Day 1. By Day 14, 42.6% of participants in COMET-2 and 53.2% in COMET-3 experienced a ≥10-mm increase in tear production, compared to only 8.2% and 14.4%, respectively, in the control groups. The treatment's effectiveness was consistent through Day 90. The most common side effect reported was mild to moderate pain at the instillation site.Expert Reactions and Future AvailabilityDr. Marjan Farid, professor of ophthalmology at the University of California, Irvine, called the approval a meaningful advancement in dry eye management, as is also reported by the US News. “Tryptyr is the first eye drop that stimulates corneal nerves to directly address tear deficiency—a known cause of dry eye disease,” she said in a statement.The treatment is expected to be launched in the U.S. by Alcon in the third quarter of 2025.Understanding Dry Eye DiseaseDry eye disease, also known by terms like dry eye syndrome (DES), ocular surface disease (OSD), and keratoconjunctivitis sicca (KCS), is one of the most common reasons people visit eye doctors. The Tear Film and Ocular Surface Society (TFOS) defines DED as a multifactorial disease of the ocular surface characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory issues.The tear film itself is about 2 to 5.5 µm thick and is made up of three main components:Lipid layer: Produced by the meibomian glands to reduce tear evaporation.Aqueous layer: The thickest layer, produced by lacrimal glands and responsible for providing hydration and nutrients.Mucin layer: Created by conjunctival goblet cells to help tears spread evenly over the eye’s surface.DES vs. DEDWhile "DES" is commonly used by both patients and clinicians, "DED" better reflects the complex nature of the condition. It accounts for various causes—ranging from evaporative issues to tear deficiency—offering a more comprehensive framework for diagnosis and treatment.With the approval of Tryptyr, the future of dry eye treatment appears more hopeful than ever.

fda greenlights tryptyr for treating dry eye disease

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.